The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, ...

Pfizer’s latest share move reflects renewed attention on its label expansion, research pipeline, dividend profile, and ...

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and ...

The treatment under review is tofacitinib, an oral drug for adults with ulcerative colitis. It targets inflammation and is already approved, so this study focuses on how it performs outside controlled ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

The FINANCIAL — Pfizer Inc. on May 23 announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX (varenicline) have been updated to include safety and ...